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This article has an accompanying continuing medical education activity on page e61. Learning Objectives—At the end of this activity, the successful
learner will be able to recognize the role of ursodeoxycholic acid in preventing primary gallbladder stones from forming during weight loss.BACKGROUND & AIMS: The prevalence of gallstones is increasing in association with the obesity epidemic, but rapid
weight loss also increases the risk of stone formation. We conducted a systematic review of the
efﬁcacy of strategies to prevent gallbladder stones in adults as they lose weight.METHODS: Randomized controlled trials of nonsurgical strategies to prevent gallstones were identiﬁed by
electronic and manual searches. Our ﬁnal analysis included 13 trials, comprising 1836 par-
ticipants undergoing weight loss through dieting (8 trials) or bariatric surgery (5 trials). The
trials compared ursodeoxycholic acid (UDCA) or high-fat weight loss diets with control in-
terventions. We performed random-effects meta-analyses and evaluated heterogeneity and bias
with subgroup, sensitivity, regression, and sequential analysis.RESULTS: UDCA reduced the risk of ultrasound-veriﬁed gallstones compared with control interventions
(risk ratio, 0.33; 95% conﬁdence interval [CI], 0.18–0.60; number needed to treat, 9). This effect
was signiﬁcantly larger in trials of diets alone (risk ratio, 0.17; 95% CI, 0.11–0.25) than in trials
of patients who underwent bariatric surgery (risk ratio, 0.42; 95% CI, 0.21–0.83) (test for
subgroup differences, P [.03). UDCA reduced the risk of cholecystectomy for symptomatic
stones (risk ratio, 0.20; 95% CI, 0.07–0.53). Diets high in fat content also reduced gallstones,
compared with those with low fat content (risk ratio, 0.09; 95% CI, 0.01–0.61). The meta-
analyses were conﬁrmed in trials with a low risk of bias but not in sequential analysis. No
additional beneﬁcial or harmful outcomes were identiﬁed.CONCLUSIONS: On the basis of a meta-analysis of randomized controlled trials, during weight loss, UDCA
and/or higher dietary fat content appear to prevent formation of gallstones.Keywords: Bariatric Surgery; Cholelithiasis; Cholesterol; Obesity.Abbreviations used in this paper: BMI, body mass index; CI, conﬁdence
interval; CSI, cholesterol saturation index; LCD, low calorie diet; NNT,
number needed to treat; RCT, randomized controlled trial; RR, risk ratio;
UDCA, ursodeoxycholic acid; VLCD, very low calorie diet; WMD, weighed
mean difference.
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Open access under CC BY-NC-ND license.The prevalence of gallstones is currently between10% and 20% in Western adults, with a projected
rise because of the obesity epidemic and increase in
metabolic syndrome and aging population.1–3 An esti-
mated 25% of gallstone carriers develop symptoms and
complications such as cholecystitis, cholangitis, and
pancreatitis.4 Patients with symptomatic gallstones fre-
quently require hospital admission and laparoscopic
cholecystectomy. Annually more than 700,000 cholecys-
tectomies are performed in the United States, which are
not only associated with speciﬁc complications such as
bile duct injury but also fatty liver disease5 and represent
a major economic burden on healthcare resources.6
Gallbladder stones comprise the common cholesterol
stones and black pigment stones.7 Currently more than30% of Americans are obese,8 and in particular, abdom-
inal obesity is an established risk factor for cholesterol
stones, because it promotes insulin resistance and biliary
cholesterol hypersecretion.9,10 A study in more than
90,000 women reported a 7-fold risk of gallstones in
morbidly obese compared with normal weight pop-
ulations.11 However, cholesterol stones also frequently
July 2014 Primary Gallstone Prevention 1091occur after rapid weight loss as a result of gallbladder
hypomotility, and cholesterol supersaturation of bile as a
result of reduced biliary bile salt secretion and enhanced
mobilization of cholesterol.12–15 During weight-reduction
dieting, gallstones may develop after just 4 weeks.15
Currently, no consensus exists with regard to gallstone
prevention in obese patients undergoingweight reduction
by bariatric surgery. Prophylactic cholecystectomy is
often proposed for these individuals,16 although the risk
of developing symptomatic gallstones might be moder-
ate.17 However, obese patients undergoing gastric bypass
surgery with concomitant cholecystectomy not only have
a risk of postoperative complications but often require
longer hospital stays.18,19
Lifestyle interventions such as physical activity or
dietary fat manipulation during dieting have been
investigated for gallstone prevention because of their
capacity to promote gallbladder motility.20 Clinical
studies with bile acids, in particular ursodeoxycholic acid
(UDCA), have demonstrated a decrease of bile lith-
ogenicity through reducing the intestinal absorption and
biliary secretion of cholesterol as well as shifting the
phase separation of bile toward solubilization in micelles
and vesicles.21,22 A seminal randomized controlled trial23
(RCT) in only 68 obese patients reported a reduced risk
of gallstone formation with UDCA administration during
weight loss on a very low calorie diet (VLCD). This
ﬁnding was corroborated in further RCTs,24,25 although
others found no effect of UDCA on gallstone prevention
during weight loss.26,27 A meta-analysis of 5 RCTs after
bariatric surgery reported a protective effect of UDCA
against gallstones during weight loss28 but did not
evaluate trials using diet alone, and it did not assess for
differences in weight loss after dieting only compared
with surgery.
Nonsurgical preventions for primary gallstones need
greater consideration, particularly because the American
Medical Association recently declared that obesity should
be categorized as a disease, requiring medical prevention
and treatment.29 Therefore, an increase in individuals at
risk for gallbladder stones is to be expected. Because
most RCTs with nonsurgical interventions include few
patients and their combined effect is unclear, we con-
ducted a systematic review and meta-analysis of RCTs to
investigate the efﬁcacy of nonsurgical preventive options
for gallbladder stones in adults during weight loss after
bariatric surgery or with diet alone.Methods
The systematic review and meta-analyses were per-
formed according to a published protocol30 and followed
the instructions in the Cochrane Handbook for Systematic
Reviews of Interventions.31,32 The main objective was to
evaluate the nonsurgical primary prevention of gall-
bladder stones, focusing on trials in patients undergoing
intended weight loss. Our primary outcome measureswere formation of ultrasonically veriﬁed gallstones,
mortality, and adverse events. Secondary outcome mea-
sures included quality of life, cholecystectomy, bile lith-
ogenicity (deﬁned as changes in physiological parameters
of bile composition indicative of an increased risk of
gallstones, eg, cholesterol saturation index [CSI],33
nucleation time for cholesterol crystal formation,34 or
presence of cholesterol crystals) and weight loss (reduc-
tion in body weight assessed in kilograms or by using the
body mass index [BMI]). Interventions were included
irrespective of the dose or class of drug. The control
groups included placebo, no intervention, or pharmaco-
logic and non-pharmacologic interventions. The threshold
for duration of therapy was set to a minimum of 4
weeks.15,35 Quasi-randomized trials and observational
studies were only eligible for inclusion in the analyses of
adverse events.Search Strategy for Identiﬁcation of Trials
We identiﬁed eligible RCTs through electronic and
manual searches. Male and female adults (older than 18
years of age) were included irrespective of ethnicity.
Participants were eligible for inclusion if they did not
have gallbladder stones at baseline veriﬁed by ultraso-
nography. We searched the Cochrane Hepato-Biliary
Group Controlled Trials Register,32 the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) in The
Cochrane Library, MEDLINE, EMBASE, and Science Cita-
tion Index Expanded. The search was performed in each
database from time of inception until July 2013
(Supplementary Table 1).
Trial registries were scanned in 2 search portals, the
U.S. National Institutes of Health (www.clinicaltrials.gov)
and the World Health Organization International Clinical
Trial Registry Platform (www.who.int/ictrp/search/en/).
We originally planned to include unpublished trials, but
no such trial was identiﬁed. Themanual search comprised
scanning reference lists of relevant articles.
All references identiﬁed in the searches were re-
viewed, and potentially eligible trials were listed and
compared against the inclusion criteria. Excluded trials
were listed with the reason for exclusion. All authors
agreed on the ﬁnal inclusion of trials. Three authors
extracted data independently by using standardized forms
(M.C., L.G., and C.S.) and resolved disagreements through
discussion. Authors of individual trials were contacted for
any unclear or missing information. Two trials were
translated into English before the data extraction.Assessment of Bias
Trials were assessed by using the Cochrane Collabo-
ration risk of bias tool.31 Information was extracted for
each trial by at least 2 authors, and risk of bias was rated
as low or high (unlikely or likely to signiﬁcantly inﬂuence
the results) or unclear with regard to the following
1092 Stokes et al Clinical Gastroenterology and Hepatology Vol. 12, No. 7domains: selection bias (including allocation sequence
generation and allocation concealment), detection and
performance bias, attrition bias, reporting bias, and other
biases such as premature termination of trials for which
predeﬁned criteria were not speciﬁed.31
Statistical Analysis
The data were analyzed by using the Cochrane Re-
view software, Review Manager 5, STATA 12 (Stata Corp,
College Station, TX) and Trial Sequential Analysis
(Copenhagen Trial Unit, Copenhagen, Denmark). The
primary meta-analyses were performed by using
random-effects models because of expected clinical het-
erogeneity. Different interventions were analyzed sepa-
rately. Fixed-effect models were used to evaluate the
robustness of the results but were only reported if they
differed from that of the random-effects models. The
measures of treatment effect were expressed as risk ra-
tios (RRs) for dichotomous data and weighted mean
differences (WMDs) for continuous outcomes, both with
95% conﬁdence intervals (CIs) and with I2 as markers of
heterogeneity. The number needed to treat (NNT) was
computed for dichotomous data when the CI did not
cross one. When trials included more than 2 intervention
groups, multiple groups were combined to create a single
pair-wise comparison.31 Data on all participants ran-
domized (irrespective of compliance or follow-up) were
sought to allow intention-to-treat analyses.
The risk of small study effects was analyzed through
regression analyses (Egger test). We performed the
following subgroup analyses to evaluate the inﬂuence of
participant type (type of weight loss method), treatment
dose (medium-to-high or low-dose UDCA, ie, 1000–1200
or 500–750 mg, respectively), initiation of UDCA in the
bariatric surgery trials, and risk of bias (low versus high
or unclear risk). Sensitivity analyses evaluated the
importance of losses to follow-up (poor outcome ana-
lyses assuming that losses to follow-up were treatment
failures and good outcome analyses assuming they were
treatment successes). We also repeated the analyses with
the 0.5 continuity correction to provide imputed data for
analysis in the trials reporting zero events in both
arms.26,36 The results of these analyses are only reported
if the conclusions differed from the primary analyses.
Cumulative meta-analyses are at risk of producing
random errors because of sparse data and multiple
testing.37–40 Therefore, trial sequential analysis was per-
formed to assess the robustness of the data.41 The
required information size was deﬁned as the number of
participants needed to detect or reject an intervention
effect and was estimated on the basis of the event pro-
portion in the control group, the observed relative risk
reduction, and the diversity (model-based heterogeneity)
of the meta-analysis.38,42 The alpha was set to 5% and the
power to 80%. On the basis of the required information
size, trial sequential monitoring boundaries were con-
structed. Firm evidence was deﬁned as being establishedif the sequential monitoring boundary was crossed before
reaching the required information size. If the boundary
was not crossed, the evidence was not conclusive.
Results
Overall, we identiﬁed 3044 references through our
electronic searches and 17 references through manual
searches (Figure 1). After excluding duplicates and ref-
erences that did not refer to trials that fulﬁlled our in-
clusion criteria, 18 references (corresponding to 16
trials) were eligible for the qualitative data synthesis; 14
references (corresponding to 13 trials) fulﬁlled our in-
clusion criteria for the meta-analysis (Table 1).
Two trials were multicenter in design,24,25 and the
remaining were single-centered. The trials were all
published as full articles from 1988–2003. One trial was
published in Italian43 and another trial in Spanish,44
which also included a short publication in English.45
The remaining trials were English language articles.
Gallstones were diagnosed by ultrasonography. One trial
used additional cholecystography,46 and another used
abdominal computed tomography scans.47
The 13 trials investigated obese participants (deﬁned
as BMI >30 kg/m2) during weight reduction. The ma-
jority of participants were female (range, 42%–100%).
Eight trials used caloric restriction (Supplementary
Table 2) based on a low calorie diet (LCD) (900–1679
kcal/day) or VLCD (<800 kcal/day). The remaining 5
trials assessed weight loss after bariatric surgery.
Two trials compared a high-fat versus low-fat weight
reducing diet.35,48 The diet in the intervention and con-
trol groups included 12.2 g versus 3.0 g fat48 or 30 g
versus 2 g fat per day.35 Overall, 11 trials assessed
300–1200 mg/day UDCA (median, 750 mg/day). The
treatment duration ranged between 6 weeks to 18
months, and the duration of follow-up ranged from 6
weeks to 24 months. Two trials included 3 different
doses of UDCA, 300/600/1200 mg.24,25 Four trials
included a third allocation arm in which participants
received 1300 mg/day acetylsalicylic acid (aspirin),23
1600 and 600 mg/day ibuprofen, respectively,26,27 or
11.3 g/day omega-3 fatty acids.36
Bias Control
None of the trials were classed as having a high risk of
bias based on the allocation methods (Supplementary
Figure 1). All trials apart from one of the dietary fat
modiﬁcation trials48 were double-blind. Seven trials were
classed as having a high risk of attrition bias because of
incomplete data on patients lost to follow-up. This was
considered the main source of bias in these trials. For 3
trials24–26 the allocation group was not speciﬁed for par-
ticipants with missing outcome data. All but 4 tri-
als23,26,35,46 included in the meta-analysis explicitly
deﬁned and reported all outcome measures. Three trials
Figure 1. Flow chart for
identiﬁcation and selection
of included randomized
trials.
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ceutical companies. This funding did not obviously affect
the overall trial design or analysis, because the trial
design, dose, and duration of the interventions assessed
did not differ from remaining trials. Two trials were
terminated early because of high attrition and slow
recruitment26 or because the incidence of symptomatic
gallstones was considered too high in the control group.35
Five trials reported power calculations,24,25,35,44,47 one of
which did not achieve the expected power.35Ursodeoxycholic Acid Interventions
As shown in Figure 2, 62 of 1217 participants (5%) in
the intervention group and 130 of 574 (23%) in the
control group of the 11 trials developed gallstones, cor-
responding to a RR of 0.33 (0.18–0.60, I2 ¼ 65%). The
corresponding NNT was 9 patients. No deaths were
reported.
We were able to extract data on cholecystectomy
because of symptomatic gallstone formation from 3 trials
on UDCA versus controls.24,47,49 Random-effects meta-
analysis showed that UDCA reduced the risk of chole-
cystectomy for symptomatic stones, with a RR of 0.20
(0.07–0.53, I2 ¼ 0%, NNT 15 patients; Supplementary
Figure 2).Because of differences in the assessment of bile lith-
ogenicity, we were unable to perform meta-analyses on
this physical-chemical outcome. Three of the trials
assessing VLCD without bariatric surgery reported de-
creases of CSI in the UDCA-treated groups and increases
in the placebo groups during follow-up as compared with
baseline,23,25,26 although this was only signiﬁcant in 2
trials.23,26
Weight loss was described as being equal in the
UDCA and placebo groups in all trials (range, 6–51
kg).23–27,36,43,44,46,47,49 We were able to include data from
4 trials in a meta-analysis, conﬁrming the ﬁnding of
equal weight loss with WMD of –0.01 (–1.07 to 1.06,
I2 ¼ 0%).23,25,36,44 Among the weight loss trials admin-
istering UDCA, Figure 3 illustrates that UDCA was more
beneﬁcial when only caloric restriction was used as
compared with bariatric surgery (test for subgroup dif-
ferences, P ¼ .03). We did not have access to individual
patient or trial level data for subgroup meta-analyses or
meta-regression analyses on the relation between base-
line weight or weight loss and intervention effects.
However, the patient characteristics in the bariatric
surgery trials indicated a higher baseline weight than
those in the diet only trials (median, 143 vs 103 kg). The
apparent weight loss was also larger in the bariatric
surgery trials (median, 41 kg; range, 25–51) compared
with dietary interventions (median, 10 kg; range, 6–25).
Table 1. Characteristics of RCTs of Nonsurgical Interventions for Primary Gallbladder Stone Prevention
Trial Country Patients (n) Intervention (dose/day)
Intervention
duration (wk)
Follow-
up (wk)
Baseline
weight (kg)
Mean weight
lost (kg)
Percentage
weight lost
Dropouts
(excluding
withdrawals)
Main inclusion
criteria
Broomﬁeld23 USA 23
22
23
VLCD þ 1200 mg UDCA,
VLCD þ 1300 mg aspirin,
VLCD þ placebo
16 19 106
98
106
21
25
21
20
26
20
5
8
4
Obese
De Filippo43 Italy 20
20
LCD þ 600 mg UDCA,
LCD þ placebo
16 16 105
101
10
8
10
8
0
0
Obese
Festi48 Italy 16
16
VLCD þ high-fat,
VLCD þ low-fat
12 12a 115
110
20
19
17
17
5
5
Obese
Gebhard35 USA 7
6
LCD þ high-fat,
VLCD þ low-fat
12 12a 114
105
25
23
22
22
0
0
Obese
Marks26 USA 16
15
16
VLCD þ 1200 mg UDCA,
VLCD þ 1600 mg ibuprofen,
VLCD þ placebo
12 12 100
110
114
10b
11b
11b
10
10
10
20c Obese
Mendez-
Sanchez36
Mexico 14
14
14
LCD þ 1200 mg UDCA,
LCD þ 11.3 g omega-3 fatty acids,
LCD þ placebo
6 6 80
84
82
6
7
6
8
8
7
4c Obese
Miller47 Austria 76
76
500 mg UDCA,
Placebo
24 96 136
136
50
51
37
38
12
16
Obese
(after bariatric surgery)
Moran44,45 Mexico 18
18
LCD þ 750 mg UDCA,
LCD þ 15 g ﬁber
8 8 90
86
6
6
7
7
0
0
Obese
Shiffman25 USA 742
255
VLCD þ 300/600/1200 mg UDCA,
VLCD þ placebo
16 16 128
129
25
24
20
19
255c Obese
Sugerman24 USA 231
74
300/600/1200 mg UDCA,
Placebo
24 24d 137
144
40
38
29
26
72c Obese
(after bariatric surgery)
Williams46 Canada 44
42
10 mg/kg UDCA,
Placebo
Up to 72 Up to 72 — 40
43
— 6
0
Obese
(after bariatric surgery)
Worobetz49 Canada 13
16
1000 mg UDCA,
Placebo
12 12 147
143
25
29
17
20
3
2
Obese
(after bariatric surgery)
Wudel27 USA 20
20
20
600 mg UDCA,
600 mg ibuprofen,
Placebo
24 48 159 48 28 5
5
9
Obese
(after bariatric surgery)
aThe entire study duration was 24 weeks; however, only the ﬁrst 12 weeks were included in this systematic review because this was the weight loss phase.
bWeight loss reported only for the 6-week time point.
cReported no signiﬁcant difference between groups.
d54 patients were followed up for 48 weeks, but only data from the 24-week time point are included.
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Figure 2.Meta-analysis of gallstone formation in obese patients receiving UDCA versus control interventions during weight
loss. M-H, Mantel-Haenszel.
July 2014 Primary Gallstone Prevention 1095The type of bariatric surgery did not inﬂuence the
effect of UDCA (test for subgroup differences, P ¼ .92).
Likewise, no difference was seen between trials that
administered the lower or higher dose of UDCA (test for
subgroup differences, P ¼ .12). A subgroup analysis
showed no difference between trials that initiated UDCA
within the ﬁrst week24,27,47,49 or 6 weeks after surgery46
(test for subgroup differences, P ¼ .26).Figure 3.Meta-analysis of gallstone formation in obese patient
loss with diet alone or after bariatric surgery. M-H, Mantel-HaeThere were no available data to assess quality of life.
There was no difference between the UDCA trials with a
low compared with a high or unclear risk of bias based on
the subgroups of trials stratiﬁed by attrition bias (P¼ .55),
reporting of outcomes (P¼ .82), or other biases (P¼ .60).
The effect of UDCAwas conﬁrmedwhen the analyseswere
repeated by using good and poor outcome analysis
(P < .0001 and P < .00001, respectively).s receiving UDCA versus control interventions during weight
nszel.
1096 Stokes et al Clinical Gastroenterology and Hepatology Vol. 12, No. 7No evidence of small study effects was identiﬁed
(Egger test, P ¼ .53). In addition, trial sequential
analysis was performed by using the trials assessing
the efﬁcacy of UDCA for gallstone prevention. On the
basis of the ﬁndings from our random-effects meta-
analysis (Figure 2), the incidence of gallstones in the
control group was set to 23% (130 of 574) in trial
sequential analysis; according to the model-based im-
putations for sequential analysis in the trial sequential
analysis program, relative risk reduction was set to
67% and model-based heterogeneity (diversity) to
77%. This analysis did not conﬁrm the result of the
meta-analysis, because the trial sequential monitoring
boundary was not crossed before reaching the
required information size (not shown). This result
suggests that the primary random-effects meta-anal-
ysis is not stable to adjustments for multiple testing
and random error.
Interventions With Dietary Fat Modiﬁcation
Two trials assessed high-fat versus low-fat weight
loss diets. The weight loss in all groups ranged from
19–25 kg.35,48 None of the 23 participants in theTable 2. Summary of Subgroup Random-effects Meta-analyses
Outcome or subgroup Stu
Gallstone formation in trials on diet alone or bariatric surgery
using available case analysis
1
Weight loss diet alone
Bariatric surgery
Gallstone formation in different types of bariatric surgery
Gastric bypass
Gastroplasty/gastric banding
Gallstone formation in relation to dose of UDCA 1
UDCA 500–750 mg
UDCA 1000–1200 mg
Gallstone formation in relation to timing of UDCA initiation
after bariatric surgery
Within 1 week
After 6 weeks
Gallstone formation in relation to attrition bias 1
Low risk of bias
High risk of bias
Gallstone formation in relation to selective reporting 1
Low risk of bias
High risk of bias
Gallstone formation in relation to other bias 1
Low risk of bias
High or unclear risk of bias
Gallstone formation good outcome analysis 1
Gallstone formation poor outcome analysis 1
Aspirin versus placebo
Aspirin versus UDCA
Ibuprofen versus placebo
Ibuprofen versus UDCA
Omega-3 fatty acids versus placebo
Omega-3 fatty acids versus UDCA
NA, not applicable; NE, not estimable.intervention group and 10 of 22 controls (45%) devel-
oped gallstones, 2 of which were symptomatic. Random-
effects meta-analysis showed that high dietary fat intake
during weight loss reduced gallstone risk (RR, 0.09;
0.01–0.61, I2 ¼ 0%, NNT 2 patients). Quality of life was
not assessed. Both trials reported a similar pattern in bile
lithogenicity in both groups but did not report data that
allowed meta-analyses. The trials described an initial
increase in lithogenicity after both diets and subse-
quently a decrease to values lower than those at baseline
during follow-up. We were unable to analyze the out-
comes of cholecystectomy or weight loss because of
differing reporting methods.
Other Interventions
The number of trials and participants assessing
aspirin, ibuprofen, and omega-3 fatty acids was small,
and few events were recorded. One trial27 found that
patients receiving ibuprofen formed gallstones at a
higher rate than the placebo or UDCA groups. This was a
trial with high attrition. Adverse events were not clearly
reported. None of the remaining interventions demon-
strated beneﬁcial or detrimental effects (Table 2).dies n
Effect estimate,
RR [95% CI]
Heterogeneity I2,
(%)
1 1470 0.34 [0.19–0.59] 66
6 949 0.17 [0.11–0.26] 0
5 521 0.40 [0.22–0.74] 59
5 612 0.42 [0.21–0.83] 64
2 345 0.45 [0.10–2.06] 87
3 267 0.42 [0.19–0.91] 38
0 1728 0.21 [0.10–0.42] 66
6 930 0.29 [0.11–0.75] 73
6 798 0.11 [0.06–0.22] 0
5 612 0.42 [0.21–0.83] 64
4 526 0.36 [0.15–0.83] 67
1 86 0.69 [0.31–1.56] NA
1 1791 0.33 [0.18–0.60] 60
5 562 0.26 [0.16–0.42] 0
6 1229 0.38 [0.12–1.22] 86
1 1791 0.33 [0.18–0.60] 65
8 1627 0.30 [0.16–0.57] 63
3 164 0.38 [0.06–2.61] 51
1 1791 0.33 [0.18–0.60] 65
5 291 0.28 [0.14–0.57] 0
6 1500 0.38 [0.17–0.86] 81
1 1791 0.39 [0.25–0.60] 37
1 1791 0.59 [0.51–0.68] 0
1 45 0.42 [0.09–1.94] NA
1 45 5.22 [0.26–102.93] NA
2 71 2.00 [1.03–3.88] NA
2 71 2.00 [1.03–3.88] NA
1 28 NE NA
1 28 NE NA
Table 3. Reported Adverse Events With UDCA Administration
Trial
Daily dose of
UDCA (mg)
No. of adverse
events in treatment
group, % (n)
Type of adverse events
in treatment group (n or %)
Type of adverse events
in control group (n or %)
Mendez-
Sanchez36
1200 13 (2) Abdominal bloating and
constipation (n ¼ 2)
Abdominal bloating and
constipation (n ¼ 2)a
Miller47 500 8 (6) Nausea, constipation (n ¼ 6)b Nausea, constipation (n ¼ 2)b
Scott50 600 25 (17) Nausea (n ¼ 9)
Diarrhea (n ¼ 5)
Dry skin/pruritus (n ¼ 3)
Not reported
Shiffman25 300/600/1200 Not reported Common complaintsb:
Constipation (27)
Headache (27)
Diarrhea (23)
Dizziness (17)
Upper respiratory infections (16)
13 patients withdrew because of
adverse events
Common complaintsb:
Constipation (26)
Headache (30)
Diarrhea (24)
Dizziness (16)
Upper respiratory infections (13)
5 patients withdrew because of
adverse events
Sugerman24 300/600/1200 Not reported Vomiting or skin rashesb Vomiting or skin rashesb
Williams46 10 (mg/kg) 9 (20) Medication intolerance (n ¼ 9)b Medication intolerance (n ¼ 7)b
Worobetz49 1000 8 (1) Epigastric burning on medication
ingestion and was withdrawn (n ¼ 1)
NOTE. Two of the trials included in the UDCA meta-analysis did not report on adverse events23,27; another 3 such trials26,43,50 plus the trial by Mok21,51 and the trial
by Mazzella52 included in the qualitative review found no adverse events in the UDCA groups.
aThese adverse events were for the group receiving omega-3 fatty acids.
bNo differences in adverse events between the placebo and intervention groups.
July 2014 Primary Gallstone Prevention 1097Adverse Events
No deaths were reported. UDCA did not increase the
risk of adverse events (Table 3). Overall, few serious
events were reported. The most common adverse events
were gastrointestinal-related complaints. Only one50 of
the three21,50–52 trials included qualitatively in this re-
view reported adverse events with UDCA supplementa-
tion. No adverse events were described in the dietary fat
modiﬁcation trials.Discussion
This systematic review suggests that UDCA and high-
fat weight loss diets may be considered in the primary
prevention of gallstones during weight loss. The number
of patients who developed gallstones in the UDCA and
control groups was 5% versus 23%, respectively. Our
results suggest that about 9 patients have to be treated
to prevent 1 patient from developing gallstones. The
NNT to prevent 1 patient from forming gallbladder
stones will depend on the baseline weight and absolute
weight loss of the included patients. No effect on mor-
tality was observed, and no major adverse effects were
reported. The effects on bile lithogenicity could not be
meta-analyzed, but some trials found improvements with
UDCA administration. This is consistent with the reduced
cholesterol supersaturation of bile, the physical-chemical
prerequisite for lowering gallstone risk.33
The observed effect in our meta-analysis seemed to
depend in part on the weight loss method, with patientsafter bariatric surgery having a smaller beneﬁt than
patients on diets alone. UDCA decreased gallstone
incidence from 19% to 3% in the diet alone trials and
from 28% to 9% in the post-bariatric surgery trials. A
curvilinear relationship between the rate of weight loss
in obese individuals and the incidence of gallstones has
been observed,53 with a weekly maximum of 1.5 kg
being assessed as optimal to limit the risk. Other evi-
dence indicates that a weight loss greater than 25%
body weight increases stone risk signiﬁcantly,54 and
this was observed in 3 of the bariatric surgery trials but
none of the diet only trials. In addition, the higher
baseline weight of the patients undergoing bariatric
surgery might have contributed to statistical differ-
ences between the 2 groups of trials. Moreover, dif-
ferences in intestinal and/or gallbladder motility,
which may be modulated by UDCA,55,56 could have
contributed to these differences, with only some of the
included trials reporting improved gallbladder con-
traction on UDCA administration.23,26,27 The observed
heterogeneity between trials mainly reﬂects differences
between the bariatric surgery trials. This might have
resulted from variations in UDCA dosage or length of
therapy (range, 12–72 weeks) and follow-up (12–96
weeks); moreover, the post-surgery diet plans might
have differed in terms of caloric composition and en-
ergy content.
In this review, a weight-reducing diet higher in fat
(19%–30%) reduced the incidence of gallstones compared
with one lower in fat (3%–5%). No adverse events were
reported, but the trials had small sample sizes. A mecha-
nistic rationale exists, because a diet higher in fat
1098 Stokes et al Clinical Gastroenterology and Hepatology Vol. 12, No. 7stimulates gallbladder contractility and may ameliorate
gallbladder hypomotility.35 In fact, both trials reported
signiﬁcant decreases in gallbladder emptying on ingestion
of a low-fat versus a high-fat meal during dieting.35,48
An important consideration is when to begin pro-
phylactic therapy. Nonsurgical trials commenced UDCA
therapy immediately on calorie restriction, whereas
bariatric surgery trials initiated UDCA within
days24,27,47,49 or weeks.46 Because gallstones may take
approximately 4 weeks to develop,15 preventive mea-
sures should begin immediately. Observational
studies55,57 report the incidence of gallstones to
approximate 36% within 6 months after gastric bypass,
and the incidence of gallstones stabilizes from there on
(eg, at 12 and 18 months). Most of the UDCA in-
terventions included in this meta-analysis lasted be-
tween 3 and 6 months, coinciding with when the
majority of weight loss occurs. This could deﬁne the
critical period for gallstone prevention in these patients.
We were unable to comment on the development of
symptomatic gallstones in all included trials, but a sub-
group analysis showed UDCA to reduce the risk of
cholecystectomy, which was consistent with recent
experimental ﬁndings58 and some clinical observa-
tions.59 Moreover, a recent meta-analysis concluded that
prophylactic cholecystectomy during laparoscopic
gastric bypass should be avoided in patients without
gallstones because of the low necessity of subsequent
cholecystectomy (<7%).60 From a cost-effectiveness
perspective, the decision to perform cholecystectomy to
prevent gallstones, particularly in obese patients under-
going weight loss, depends on the incidence of
gallbladder-related symptoms after surgery.61 A study
following 13,443 participants after bariatric surgery for
22 years reported a low incidence of gallstones, and the
majority were asymptomatic.62 Hence, a conventional
nonsurgical approach for stone prevention may be
preferred.
The small number of identiﬁed trials and corre-
spondingly low sample sizes for some of the meta-
analyses are the main limitation of this review.
Several clinically relevant outcomes were also not
addressed, in particular, quality of life measures.
Moreover, a high risk of attrition bias was identiﬁed
because several trials reported high dropout rates. The
complexity with these trials is that participants were
following a weight loss diet (as co-intervention) that, by
default, yields high attrition.63 It is possible that the
poor compliance reﬂects the difﬁculty in following the
weight loss diets rather than the interventions for pri-
mary stone prevention. In support of this, many trials
did not ﬁnd signiﬁcant differences in attrition or in
adverse events between the treatment and control
groups. Finally, the data did not allow a meta-analysis of
other interventions that reduce cholesterol precipitation
in bile in preclinical or nonrandomized studies (eg,
nonsteroidal anti-inﬂammatory drugs) with potential to
prevent gallstones.64Conclusions and Clinical Implications
Because both the obesity epidemic and weight loss
interventions in obese patients increase the risk of gall-
stones, we will be faced with a higher incidence of gall-
stones. Nonsurgical options for the primary prevention
of gallstones currently remain underused. Evidence-
based guidelines are needed to guide preventive in-
terventions for clinical practice. The meta-analysis herein
suggests that UDCA and/or a diet higher in fat might
decrease the overall risk of gallbladder stones forming
during weight loss, albeit the subgroup of patients who
goes on to develop symptomatic gallstones needs to be
better deﬁned. In future, multifactorial models based on
the combination of clinical and genetic factors65,66 might
help in the precise identiﬁcation of the patients who are
at highest risk of symptomatic stones and likely to
beneﬁt most from nonsurgical gallstone prevention.Supplementary Material
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Supplementary Figure 1. Assessment of bias.
Supplementary Figure 2.Meta-analysis of obese patients requiring cholecystectomy after receiving UDCA vs control in-
terventions during weight loss.
Supplementary Table 1. Full Electronic Search
#1 MeSH descriptor Ultrasonography explode all trees
#2 ultrasonograph* OR ultrasound* OR ecograph*
#3 (#1 OR #2)
#4 MeSH descriptor Ursodeoxycholic Acid explode all trees
#5 ursodeoxycholic acid* OR ursodiol OR UDCA
#6 (#4 OR #5)
#7 MeSH descriptor Anti-Inﬂammatory Agents, Non-Steroidal
explode all trees
#8 (non-steroid* anti-inﬂammatory AND (drug* OR agent*)) OR
ibuprofen OR aspirin
#9 (#7 OR #8)
#10 MeSH descriptor Obesity explode all trees
#11 obesity
#12 (#10 OR #11)
#13 MeSH descriptor Bariatric Surgery explode all trees
#14 bariatric surger*
#15 (#13 OR #14)
#16 MeSH descriptor Weight Loss explode all trees
#17 weight loss*
#18 (#16 OR #17)
#19 MeSH descriptor Diet Therapy explode all trees
#20 diet therap* OR caloric restriction OR low calorie diet* OR liquid
diet* OR fat* OR protein* OR carbohydrate* OR ﬁbre
#21 (#19 OR #20)
#22 MeSH descriptor Micronutrients explode all trees
#23 micronutrient*
#24 (#22 OR #23)
#25 MeSH descriptor Exercise explode all trees
#26 physical activit* OR exercise*
#27 (#25 OR #26)
#28 (#3 OR #6 OR #9 OR #12 OR #15 OR #18 OR #21 OR #24
OR #27)
#29 MeSH descriptor Cholelithiasis explode all trees
#30 cholelithiasis OR gallstone* OR gall* stone* OR ’black pigment
stone*’
#31 (#29 OR #30)
#32 (#28 AND #31)
NOTE. Example given for the Cochrane Central Register for Controlled Trials in
the Cochrane Library.
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Supplementary Table 2. Dietary Composition of Weight Loss Diets
Trial kcal Protein (g) Carbohydrates (g) Fat (g) Fiber (g) Cholesterol (mg)
Broomﬁeld23 520 55 79 1
De Filippo43 1000–1200 60–70 100–170 20–43 35–40 165–220
Festi48
Intervention 577 55 61.7 12.2
Control 535.2 44.4 82.2 3
Gebhard35
Intervention 900 90 68 30 90
Control 520 50 76 <2 30
Marks26 520 NR NR NR
Mendez-Sanchez36 1200 60 180 27
Moran44,45 1679a 67 248 48 20
Shiffman25 520 50 79 1–3
NR, not reported.
aEach patient had to reduce their total energy intake by 500 kcal and was instructed to follow a diet with 15% protein, 60% carbohydrate, and 25% fat, as
speciﬁed above.
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